Kintara Therapeutics (Kintara Therapeutics) ROCE % : 0.00% (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Kintara Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kintara Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was 0.00%.

Kintara Therapeutics ROCE % Historical Data

The historical data trend for Kintara Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics ROCE % Chart

Kintara Therapeutics Annual Data

Trend

Dec13

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-226.88

-730.40

-391.29

-199.66

-230.20

Kintara Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-170.97	-248.55	-552.75	-	-

Kintara Therapeutics ROCE % Calculation

Kintara Therapeutics's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-14.796	/	( ( (15.948 - 3.99)	+	(3.979 - 3.082) )	/ 2 )
	=	-14.796	/	( (11.958	+	0.897)	/ 2 )
	=	-14.796	/	6.4275
	=	-230.20 %

Kintara Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-4.076	/	( ( (1.477 - 3.336)	+	(1.885 - 1.87) )	/ 2 )
	=	-4.076	/	( ( -1.859	+	0.015 )	/ 2 )
	=	-4.076	/	-0.922
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Kintara Therapeutics (NAS:KTRA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kintara Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintara Therapeutics (Kintara Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (NAS:KTRA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

3DMA:Germany 3DMA:Germany

Address

9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121

Website

https://www.kintara.com

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Executives

Robert Hoffman	director, officer: President and CEO	ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Anthony Scott Praill	officer: Chief Financial Officer	2001-889 HOMER STREET, VANCOUVER A1 V6B 5S3
Saiid Zarrabian	director, officer: Head of Strategic Partnerships	P.O. BOX 675765, RANCHO SANTA FE CA 92067
Laura L. Johnson	director	C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Tamara A Seymour	director	C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Toth Robert Joseph Jr	director	543 LOMBARD ST, SAN FRANCISCO CA 94133
Dennis M Brown	officer: Chief Scientific Officer	100 SAN MATEO DR, MENLO PARK CA 94025
Keith Murphy	director	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
John Liatos	director, officer: SVP, Business Development	12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
John K Bell	director	38 FALLBROOK LANE RR 33, CAMBRIDGE A6 N3H 4R8
Napoleone Ferrara	director	550 FRONT STREET, UNIT 1103, SAN DIEGO CA 92101
Lynda Sarah Cranston	director	4316 LOCARNO CRESCENT, VANCOUVER A1 V6R 1G3
Erich Mohr	director	8300 GREENSBORO DRIVE, MCLEAN VA 22102
Jeffrey Bacha	director	SUITE 3 1545 WEST 14TH AVENUE, VANCOUVER A1 V6J 2J1
William J Garner	director	875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010